Biohaven BHVN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Biohaven (BHVN) Business Model and Operations Summary
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Key Insights
Biohaven (BHVN) Core Market Data and Business Metrics
Latest Closing Price
$23.68Market Cap
$2.42 BillionPrice-Earnings Ratio
-6.96Total Outstanding Shares
102.07 Million SharesTotal Employees
256Dividend
No dividendIPO Date
September 23, 2022SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
215 Church Street, New Haven, CT, 06510
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,520,937 Shares | 4.82 | 3/14/2025 | 7,329,609 Shares |
| 708,568 Shares | 11.69 | 2/28/2025 | 8,282,970 Shares |
| 823,337 Shares | 10.47 | 2/14/2025 | 8,617,707 Shares |
| 855,848 Shares | 11.03 | 1/31/2025 | 9,438,778 Shares |
| 1,095,281 Shares | 9.08 | 1/15/2025 | 9,940,311 Shares |
| 1,358,146 Shares | 7.16 | 12/31/2024 | 9,717,699 Shares |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $0 |
| Net Cash Flow From Investing Activities, Continuing | $-93.40 Million |
| Net Cash Flow From Investing Activities | $-93.40 Million |
| Net Cash Flow, Continuing | $-154.30 Million |
| Net Cash Flow From Financing Activities, Continuing | $80.38 Million |
| Net Cash Flow From Financing Activities | $80.38 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Revenues | $0 |
| Net Income/Loss Attributable To Parent | $-160.30 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-160.30 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Basic Earnings Per Share | $-1.70 |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-160.09 Million |
| Comprehensive Income/Loss Attributable To Parent | $-160.09 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $218,000 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $316.01 Million |
| Noncurrent Assets | $70.02 Million |
| Wages | $15.88 Million |
| Noncurrent Liabilities | $42.22 Million |
| Current Assets | $440.50 Million |
| Fixed Assets | $18.28 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||